What is ViewsML?
ViewsML operates at the intersection of advanced computational biology and clinical oncology. The company specializes in AI-powered virtual diagnostics that accelerate the detection of biomarkers, providing results in seconds rather than days. This technological capability is designed to optimize clinical workflows, reduce operational costs for contract research organizations, and enhance patient stratification across diverse therapeutic areas. By facilitating faster, more accurate data analysis, ViewsML addresses the critical need for efficiency in preclinical and translational research, ultimately aiming to improve patient outcomes through data-driven precision medicine.
How much funding has ViewsML raised?
ViewsML has raised a total of $4.9M across 1 funding round:
Seed
$4.9M
Seed (2026): $4.9M with participation from Continuum Ventures, RiSC Capital, Wittington Ventures, Debiopharm, and Wutif
Key Investors in ViewsML
Continuum Ventures
An early-stage venture capital fund focused on Healthtech and TechBio, dedicated to transforming healthcare through preventative, AI-driven solutions.
RiSC Capital
A Canadian deep tech venture capital firm specializing in seed and pre-seed stage investments, providing strategic engineering-led guidance to high-growth startups.
Wittington Ventures
A private family investment firm with a long-standing history of managing diverse portfolios and strategic interests across multiple sectors.
What's next for ViewsML?
With this major enterprise-level funding, ViewsML is poised to scale its diagnostic platform across global clinical research markets. The strategic infusion of capital will likely be directed toward expanding the company's biomarker detection capabilities and deepening its integration within existing hospital and laboratory information systems. As the firm transitions from its initial development phase into a broader commercialization strategy, the focus will remain on enhancing the scalability of its deep learning models to support larger, more complex datasets. Investors are closely monitoring the company's ability to maintain its competitive edge in the rapidly evolving healthtech landscape, particularly as it seeks to standardize its virtual diagnostic tools for widespread adoption in oncology research.
See full ViewsML company page
